Innovative Investor Event by Calidi Biotherapeutics
Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a pioneering clinical-stage biotechnology company, is gearing up to host an exciting investor event. This event will take place within the prestigious Society for Immunotherapy of Cancer (SITC) Annual Meeting, showcasing the company’s transformative RedTail platform and its leading candidate, CLD-401.
Event Details
This important investor event is scheduled for a Friday morning during the SITC Annual Meeting. It will offer an insightful overview of the groundbreaking work Calidi is undertaking in the realm of genetic medicines. The session will be held in the National Harbor Room 15 at the Gaylord National Hotel and Convention Center.
Agenda Highlights
Attendees can expect to hear from a formidable lineup of experts in the field of cancer research and treatment. The event will include presentations from:
- Dr. Dmitriy Zamarin from the Icahn School of Medicine, whose expertise in virotherapy is complemented by his role on Calidi’s Scientific Advisory Board.
- Dr. Antonio F. Santidrian, the Chief Scientific Officer at Calidi, who spearheads the company's research initiatives.
- Dr. John M. Wrangle, an esteemed oncologist with a focus on IL-15 superagonist development and also a member of Calidi's advisory team.
- Dr. Travis Clifton, Calidi's Chief Medical Officer, who brings over 17 years of experience in drug development and cancer immunotherapy.
Significance of the Presentation
CEO Eric Poma expressed enthusiasm about hosting their first investor event, confidently stating that CLD-401 and the RedTail platform hold groundbreaking potential in genetic medicine. This presentation aims to inform the investment community about the Company’s advancements.
Future Prospects for CLD-401
Currently, Calidi is conducting vital IND-enabling studies for CLD-401, with intentions to file an Investigational New Drug application by the end of 2026. The company is actively seeking strategic partnerships to enhance the clinical development and reach of its innovative RedTail platform.
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) stands out as a clinical-stage company that is developing targeted therapies designed to deliver genetic medications effectively to critical sites within the body. Their proprietary RedTail platform utilizes an engineered enveloped oncolytic virus for systemic delivery that targets metastatic disease locations, protecting the virus from immune response to enhance efficacy.
Broad Applications of CLD-401
CLD-401, the flagship candidate from this groundbreaking platform, is pivotal in targeting various high-need cancers, including non-small cell lung cancer and head and neck cancer. Its unique approach to therapy holds promise in treating patients who have limited options.
Contact Information
For all investor inquiries, please contact Dave Gentry, CEO of RedChip Companies, at 1-407-644-4256, or via email at CLDI@redchip.com.
Frequently Asked Questions
What is the focus of Calidi Biotherapeutics?
Calidi Biotherapeutics focuses on developing targeted genetic therapies, primarily through their innovative RedTail platform, to combat cancer.
When will the investor event take place?
The investor event is scheduled for Friday morning during the SITC Annual Meeting.
Who are the key speakers at the event?
Key speakers include Dr. Dmitriy Zamarin, Dr. Antonio F. Santidrian, Dr. John M. Wrangle, and Dr. Travis Clifton.
What is the significance of CLD-401?
CLD-401 is central to Calidi's efforts, targeting cancers with a high unmet medical need and featuring innovative delivery methods.
How can I get more information about Calidi?
For more details, visit www.calidibio.com.
